India is undergoing a steady but serious public health shift. For decades, obesity was long dismissed as a matter of personal discipline, a “lifestyle choice,” to be managed by sheer willpower.

The US has stricter food labelling than India, yet 40.3 percent of American adults are obese versus 23 to 24 percent of ...

New Delhi: Finance Minister Nirmala Sitharaman on Thursday tabled India’s Economic Survey 2025–26 in Parliament ahead of the Union Budget, offering the first official assessment of the economy and ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: An employee inspects tablets as they move along the production line at a pharmaceutical plant of Lupin, India's No. 2 ...

HYDERABAD, India, Dec 24 (Reuters) - Global pharma giants Eli Lilly and Novo Nordisk are scrambling to cement their lead in India's booming ‌obesity drug market before cheaper generic versions hit ...

Following PM Modi’s call to curb obesity, India’s FSSAI is urging states to cut oil use by 10% and roll out ‘sugar boards’ to promote healthier diets in schools Indian authorities have urged all ...

A deluge of weight-loss drugs is set to transform the global fight against obesity as India prepares to unleash low-cost generic versions of injections like Ozempic after a key patent expired Friday.

HYDERABAD, Nov 6 (Reuters) - Popular weight-loss drug Wegovy maker Novo Nordisk (NOVOb.CO), opens new tab expects high demand and acceptance for its anti-obesity drug, when launched in India, a top ...

HYDERABAD, Feb 28 (Reuters) - U.S. drugmaker Eli Lilly LLY.N expects to launch Mounjaro, its blockbuster diabetes drug and a wildly popular obesity treatment, in India as early as next year, CEO David ...

BENGALURU, June 28 (Reuters) - India is planning to offer incentives to promote local manufacturing of GLP-1 drugs used to treat diabetes and obesity, in 2026, a top government official said on Friday ...

Feb 28 (Reuters) - Eli Lilly LLY.N expects to launch its obesity drug tirzepatide in India as early as next year, the U.S. drugmaker's CEO David Ricks told Reuters on Wednesday. "We're open to any way ...